Colorcon to Open Film Coating Manufacturing Facility in Brazil
The new facility will produce GMP film coating productions for the pharmaceutical and nutritional markets in South America.
Colorcon announced on May 4, 2016 that it has invested in a new film coating manufacturing plant in Indaiatuba – São Paulo State, Brazil, the company said in a press announcement. Construction on the facility is scheduled for completion by October 2016 with the production of commercial scale product scheduled for January 2017, the company said. Colorcon wrote the new facility will produce GMP film coating productions for the pharmaceutical and nutritional markets in South America, including Argentina, Brazil, Chile, Paraguay, and Uruguay.
The new facility will aid in the formulation and development of pharmaceutical products through the company’s Technical Service Laboratory, which is already established in Cotia, São Paulo. The Cotia location was opened in 2000, and provides samples and applications support.
Source: Colorcon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
